Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma

Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma.

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma

Isolated metastases from gastric adenocarcinoma to the spleen are very infrequent. Usually, there are multiple metastases from gastric cancer, and isolated splenic metastases are very rare [Lam and Tang: Arch Pathol Lab Med 2000;124:526-530] because of certain anatomical and physiological characteristics (e.g., angulation between the splenic artery and celiac trunk, paucity of afferent lymph fl...

HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population

BACKGROUND With varied immunohistochemistry scoring criteria and patient cohorts, HER2-positivity rates in gastric cancer (GC) and gastroesophageal junction (GEJ) adenocarcinoma have been reported with a wide range. Recently standardized scoring criteria for GC and GEJ cancer has been established and recommended. In this study, the frequency of HER2 expression and the relationship between HER2 ...

The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel

Human epidermal growth factor 2 (HER2) positivity rates for gastric or gastroesophageal junction (GEJ) adenocarcinoma have been reported at 15-25%. Cyclin D1 (BCL1) is a non-specific proliferative marker. The prognostic significance of HER2 and cyclin D1 is inconclusive, with contradictory data. The aim of this study was to evaluate the incidence of HER2 overexpression in gastric or GEJ patient...

HER2/neu Expression in Gastric and Esophagogastric Junction Adenocarcinoma

Background: Gastric cancer is one of the most commonly diagnosed cancer and one of the most common causes of cancerrelated deaths worldwide. HER-2/neu, a well-recognized factor, is indicated in the development of certain human solid tumors, notably breast cancer. High expression of HER2/neu has correlated with poor prognosis. Studies reveal combination of treatment with antibody targeting HER-2...